Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Breye Therapeutics United States of America Denmark United Kingdom

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakageData support continued advancement into Phase 2 clinical evaluationView original content:https://www.prnewswire.co.uk/news-releases/breye-therapeutics-announces-successful-completion-of-its-phase-1b-trial-with-danegaptide-in-patients-with-diabetic-retinopathy-302488407.html